Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy

NCT00772694 is registered in ClinicalTrials.gov with Fondation Wygrajmy Zdrowie as lead sponsor.

NCT NCT00772694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00772694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
Lead sponsor
Fondation Wygrajmy Zdrowie
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2008
Completion date
December 31, 2011
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

testicular cancer